Lakefront Biotherapeutics (LKFT) Assets Average (2015 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Assets Average for 11 consecutive years, with $3.9 billion the latest figure, recorded in Q1 2026.

• Quarterly Assets Average fell 16.9% year-over-year to $3.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 billion (down 16.9% YoY) and the FY2025 annual result came in at $4.3 billion, down 11.2% from the prior year.
• Assets Average fell to $3.9 billion in Q1 2026 per LKFT's latest filing, from $3.9 billion in the prior quarter.
• Over the last five years, Assets Average for LKFT reached as high as $5.9 billion in Q1 2022 and fell as low as $3.9 billion in Q1 2026.
• A 5-year average of $4.7 billion and a median of $4.7 billion in 2025 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2024 — Assets Average retreated 5.69% — and 2026, when it slipped 16.9%.
• Year by year, Assets Average stood at $5.9 billion in 2022, then decreased by 14.42% to $5.0 billion in 2023, then slipped by 5.69% to $4.7 billion in 2024, then declined by 16.72% to $3.9 billion in 2025, then decreased by 2.02% to $3.9 billion in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $3.9 billion, $3.9 billion, and $4.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.